Medical Care
Global Lung Cancer Therapeutics Market Research Report 2025
- Jul 08, 25
- ID: 347724
- Pages: 80
- Figures: 71
- Views: 1
The global market for Lung Cancer Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Lung Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Therapeutics.
The Lung Cancer Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Lung Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lung Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Eli Lilly and Company
GlaxoSmithKline
Roche
Boehringer Ingelheim GmbH
Pfizer
Sanofi S.A.
Bristol-Myers Squibb
Novartis
Agennix AG
Segment by Type
Targeted Therapy
Immunotherapy
Chemotherapy
Radiation Therapy
Others
Segment by Application
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lung Cancer Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Lung Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Therapeutics.
The Lung Cancer Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Lung Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lung Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Eli Lilly and Company
GlaxoSmithKline
Roche
Boehringer Ingelheim GmbH
Pfizer
Sanofi S.A.
Bristol-Myers Squibb
Novartis
Agennix AG
Segment by Type
Targeted Therapy
Immunotherapy
Chemotherapy
Radiation Therapy
Others
Segment by Application
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lung Cancer Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lung Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Targeted Therapy
1.2.3 Immunotherapy
1.2.4 Chemotherapy
1.2.5 Radiation Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Lung Cancer Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Non-Small Cell Lung Cancer (NSCLC)
1.3.3 Small Cell Lung Cancer (SCLC)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lung Cancer Therapeutics Market Perspective (2020-2031)
2.2 Global Lung Cancer Therapeutics Growth Trends by Region
2.2.1 Global Lung Cancer Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Lung Cancer Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Lung Cancer Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Lung Cancer Therapeutics Market Dynamics
2.3.1 Lung Cancer Therapeutics Industry Trends
2.3.2 Lung Cancer Therapeutics Market Drivers
2.3.3 Lung Cancer Therapeutics Market Challenges
2.3.4 Lung Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lung Cancer Therapeutics Players by Revenue
3.1.1 Global Top Lung Cancer Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Lung Cancer Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Lung Cancer Therapeutics Revenue
3.4 Global Lung Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lung Cancer Therapeutics Revenue in 2024
3.5 Global Key Players of Lung Cancer Therapeutics Head office and Area Served
3.6 Global Key Players of Lung Cancer Therapeutics, Product and Application
3.7 Global Key Players of Lung Cancer Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Lung Cancer Therapeutics Breakdown Data by Type
4.1 Global Lung Cancer Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Lung Cancer Therapeutics Forecasted Market Size by Type (2026-2031)
5 Lung Cancer Therapeutics Breakdown Data by Application
5.1 Global Lung Cancer Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Lung Cancer Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Lung Cancer Therapeutics Market Size (2020-2031)
6.2 North America Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Lung Cancer Therapeutics Market Size by Country (2020-2025)
6.4 North America Lung Cancer Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lung Cancer Therapeutics Market Size (2020-2031)
7.2 Europe Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Lung Cancer Therapeutics Market Size by Country (2020-2025)
7.4 Europe Lung Cancer Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Lung Cancer Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Lung Cancer Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Lung Cancer Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lung Cancer Therapeutics Market Size (2020-2031)
9.2 Latin America Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Lung Cancer Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Lung Cancer Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Lung Cancer Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Lung Cancer Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Lung Cancer Therapeutics Introduction
11.1.4 AstraZeneca Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.1.5 AstraZeneca Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Lung Cancer Therapeutics Introduction
11.2.4 Eli Lilly and Company Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.2.5 Eli Lilly and Company Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Lung Cancer Therapeutics Introduction
11.3.4 GlaxoSmithKline Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.3.5 GlaxoSmithKline Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Lung Cancer Therapeutics Introduction
11.4.4 Roche Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.4.5 Roche Recent Development
11.5 Boehringer Ingelheim GmbH
11.5.1 Boehringer Ingelheim GmbH Company Details
11.5.2 Boehringer Ingelheim GmbH Business Overview
11.5.3 Boehringer Ingelheim GmbH Lung Cancer Therapeutics Introduction
11.5.4 Boehringer Ingelheim GmbH Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.5.5 Boehringer Ingelheim GmbH Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Lung Cancer Therapeutics Introduction
11.6.4 Pfizer Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.6.5 Pfizer Recent Development
11.7 Sanofi S.A.
11.7.1 Sanofi S.A. Company Details
11.7.2 Sanofi S.A. Business Overview
11.7.3 Sanofi S.A. Lung Cancer Therapeutics Introduction
11.7.4 Sanofi S.A. Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.7.5 Sanofi S.A. Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Details
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Lung Cancer Therapeutics Introduction
11.8.4 Bristol-Myers Squibb Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Lung Cancer Therapeutics Introduction
11.9.4 Novartis Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.9.5 Novartis Recent Development
11.10 Agennix AG
11.10.1 Agennix AG Company Details
11.10.2 Agennix AG Business Overview
11.10.3 Agennix AG Lung Cancer Therapeutics Introduction
11.10.4 Agennix AG Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.10.5 Agennix AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lung Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Targeted Therapy
1.2.3 Immunotherapy
1.2.4 Chemotherapy
1.2.5 Radiation Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Lung Cancer Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Non-Small Cell Lung Cancer (NSCLC)
1.3.3 Small Cell Lung Cancer (SCLC)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lung Cancer Therapeutics Market Perspective (2020-2031)
2.2 Global Lung Cancer Therapeutics Growth Trends by Region
2.2.1 Global Lung Cancer Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Lung Cancer Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Lung Cancer Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Lung Cancer Therapeutics Market Dynamics
2.3.1 Lung Cancer Therapeutics Industry Trends
2.3.2 Lung Cancer Therapeutics Market Drivers
2.3.3 Lung Cancer Therapeutics Market Challenges
2.3.4 Lung Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lung Cancer Therapeutics Players by Revenue
3.1.1 Global Top Lung Cancer Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Lung Cancer Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Lung Cancer Therapeutics Revenue
3.4 Global Lung Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lung Cancer Therapeutics Revenue in 2024
3.5 Global Key Players of Lung Cancer Therapeutics Head office and Area Served
3.6 Global Key Players of Lung Cancer Therapeutics, Product and Application
3.7 Global Key Players of Lung Cancer Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Lung Cancer Therapeutics Breakdown Data by Type
4.1 Global Lung Cancer Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Lung Cancer Therapeutics Forecasted Market Size by Type (2026-2031)
5 Lung Cancer Therapeutics Breakdown Data by Application
5.1 Global Lung Cancer Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Lung Cancer Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Lung Cancer Therapeutics Market Size (2020-2031)
6.2 North America Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Lung Cancer Therapeutics Market Size by Country (2020-2025)
6.4 North America Lung Cancer Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lung Cancer Therapeutics Market Size (2020-2031)
7.2 Europe Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Lung Cancer Therapeutics Market Size by Country (2020-2025)
7.4 Europe Lung Cancer Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Lung Cancer Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Lung Cancer Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Lung Cancer Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lung Cancer Therapeutics Market Size (2020-2031)
9.2 Latin America Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Lung Cancer Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Lung Cancer Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Lung Cancer Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Lung Cancer Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Lung Cancer Therapeutics Introduction
11.1.4 AstraZeneca Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.1.5 AstraZeneca Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Lung Cancer Therapeutics Introduction
11.2.4 Eli Lilly and Company Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.2.5 Eli Lilly and Company Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Lung Cancer Therapeutics Introduction
11.3.4 GlaxoSmithKline Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.3.5 GlaxoSmithKline Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Lung Cancer Therapeutics Introduction
11.4.4 Roche Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.4.5 Roche Recent Development
11.5 Boehringer Ingelheim GmbH
11.5.1 Boehringer Ingelheim GmbH Company Details
11.5.2 Boehringer Ingelheim GmbH Business Overview
11.5.3 Boehringer Ingelheim GmbH Lung Cancer Therapeutics Introduction
11.5.4 Boehringer Ingelheim GmbH Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.5.5 Boehringer Ingelheim GmbH Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Lung Cancer Therapeutics Introduction
11.6.4 Pfizer Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.6.5 Pfizer Recent Development
11.7 Sanofi S.A.
11.7.1 Sanofi S.A. Company Details
11.7.2 Sanofi S.A. Business Overview
11.7.3 Sanofi S.A. Lung Cancer Therapeutics Introduction
11.7.4 Sanofi S.A. Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.7.5 Sanofi S.A. Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Details
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Lung Cancer Therapeutics Introduction
11.8.4 Bristol-Myers Squibb Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Lung Cancer Therapeutics Introduction
11.9.4 Novartis Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.9.5 Novartis Recent Development
11.10 Agennix AG
11.10.1 Agennix AG Company Details
11.10.2 Agennix AG Business Overview
11.10.3 Agennix AG Lung Cancer Therapeutics Introduction
11.10.4 Agennix AG Revenue in Lung Cancer Therapeutics Business (2020-2025)
11.10.5 Agennix AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Targeted Therapy
Table 3. Key Players of Immunotherapy
Table 4. Key Players of Chemotherapy
Table 5. Key Players of Radiation Therapy
Table 6. Key Players of Others
Table 7. Global Lung Cancer Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Lung Cancer Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Lung Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Lung Cancer Therapeutics Market Share by Region (2020-2025)
Table 11. Global Lung Cancer Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Lung Cancer Therapeutics Market Share by Region (2026-2031)
Table 13. Lung Cancer Therapeutics Market Trends
Table 14. Lung Cancer Therapeutics Market Drivers
Table 15. Lung Cancer Therapeutics Market Challenges
Table 16. Lung Cancer Therapeutics Market Restraints
Table 17. Global Lung Cancer Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Lung Cancer Therapeutics Market Share by Players (2020-2025)
Table 19. Global Top Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Cancer Therapeutics as of 2024)
Table 20. Ranking of Global Top Lung Cancer Therapeutics Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Lung Cancer Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Lung Cancer Therapeutics, Headquarters and Area Served
Table 23. Global Key Players of Lung Cancer Therapeutics, Product and Application
Table 24. Global Key Players of Lung Cancer Therapeutics, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Lung Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Lung Cancer Therapeutics Revenue Market Share by Type (2020-2025)
Table 28. Global Lung Cancer Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Lung Cancer Therapeutics Revenue Market Share by Type (2026-2031)
Table 30. Global Lung Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Lung Cancer Therapeutics Revenue Market Share by Application (2020-2025)
Table 32. Global Lung Cancer Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Lung Cancer Therapeutics Revenue Market Share by Application (2026-2031)
Table 34. North America Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Lung Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Lung Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Lung Cancer Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 49. AstraZeneca Company Details
Table 50. AstraZeneca Business Overview
Table 51. AstraZeneca Lung Cancer Therapeutics Product
Table 52. AstraZeneca Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 53. AstraZeneca Recent Development
Table 54. Eli Lilly and Company Company Details
Table 55. Eli Lilly and Company Business Overview
Table 56. Eli Lilly and Company Lung Cancer Therapeutics Product
Table 57. Eli Lilly and Company Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 58. Eli Lilly and Company Recent Development
Table 59. GlaxoSmithKline Company Details
Table 60. GlaxoSmithKline Business Overview
Table 61. GlaxoSmithKline Lung Cancer Therapeutics Product
Table 62. GlaxoSmithKline Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 63. GlaxoSmithKline Recent Development
Table 64. Roche Company Details
Table 65. Roche Business Overview
Table 66. Roche Lung Cancer Therapeutics Product
Table 67. Roche Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 68. Roche Recent Development
Table 69. Boehringer Ingelheim GmbH Company Details
Table 70. Boehringer Ingelheim GmbH Business Overview
Table 71. Boehringer Ingelheim GmbH Lung Cancer Therapeutics Product
Table 72. Boehringer Ingelheim GmbH Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 73. Boehringer Ingelheim GmbH Recent Development
Table 74. Pfizer Company Details
Table 75. Pfizer Business Overview
Table 76. Pfizer Lung Cancer Therapeutics Product
Table 77. Pfizer Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 78. Pfizer Recent Development
Table 79. Sanofi S.A. Company Details
Table 80. Sanofi S.A. Business Overview
Table 81. Sanofi S.A. Lung Cancer Therapeutics Product
Table 82. Sanofi S.A. Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 83. Sanofi S.A. Recent Development
Table 84. Bristol-Myers Squibb Company Details
Table 85. Bristol-Myers Squibb Business Overview
Table 86. Bristol-Myers Squibb Lung Cancer Therapeutics Product
Table 87. Bristol-Myers Squibb Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 88. Bristol-Myers Squibb Recent Development
Table 89. Novartis Company Details
Table 90. Novartis Business Overview
Table 91. Novartis Lung Cancer Therapeutics Product
Table 92. Novartis Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 93. Novartis Recent Development
Table 94. Agennix AG Company Details
Table 95. Agennix AG Business Overview
Table 96. Agennix AG Lung Cancer Therapeutics Product
Table 97. Agennix AG Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 98. Agennix AG Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
Table 102. Authors List of This Report
List of Figures
Figure 1. Lung Cancer Therapeutics Picture
Figure 2. Global Lung Cancer Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Lung Cancer Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Targeted Therapy Features
Figure 5. Immunotherapy Features
Figure 6. Chemotherapy Features
Figure 7. Radiation Therapy Features
Figure 8. Others Features
Figure 9. Global Lung Cancer Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Lung Cancer Therapeutics Market Share by Application: 2024 VS 2031
Figure 11. Non-Small Cell Lung Cancer (NSCLC) Case Studies
Figure 12. Small Cell Lung Cancer (SCLC) Case Studies
Figure 13. Lung Cancer Therapeutics Report Years Considered
Figure 14. Global Lung Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Lung Cancer Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Lung Cancer Therapeutics Market Share by Region: 2024 VS 2031
Figure 17. Global Lung Cancer Therapeutics Market Share by Players in 2024
Figure 18. Global Top Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Cancer Therapeutics as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Lung Cancer Therapeutics Revenue in 2024
Figure 20. North America Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 22. United States Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 26. Germany Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Lung Cancer Therapeutics Market Share by Region (2020-2031)
Figure 34. China Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 42. Mexico Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 46. Turkey Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. AstraZeneca Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 50. Eli Lilly and Company Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 51. GlaxoSmithKline Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 52. Roche Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 53. Boehringer Ingelheim GmbH Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 54. Pfizer Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 55. Sanofi S.A. Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 57. Novartis Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 58. Agennix AG Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Table 1. Global Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Targeted Therapy
Table 3. Key Players of Immunotherapy
Table 4. Key Players of Chemotherapy
Table 5. Key Players of Radiation Therapy
Table 6. Key Players of Others
Table 7. Global Lung Cancer Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Lung Cancer Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Lung Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Lung Cancer Therapeutics Market Share by Region (2020-2025)
Table 11. Global Lung Cancer Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Lung Cancer Therapeutics Market Share by Region (2026-2031)
Table 13. Lung Cancer Therapeutics Market Trends
Table 14. Lung Cancer Therapeutics Market Drivers
Table 15. Lung Cancer Therapeutics Market Challenges
Table 16. Lung Cancer Therapeutics Market Restraints
Table 17. Global Lung Cancer Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Lung Cancer Therapeutics Market Share by Players (2020-2025)
Table 19. Global Top Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Cancer Therapeutics as of 2024)
Table 20. Ranking of Global Top Lung Cancer Therapeutics Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Lung Cancer Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Lung Cancer Therapeutics, Headquarters and Area Served
Table 23. Global Key Players of Lung Cancer Therapeutics, Product and Application
Table 24. Global Key Players of Lung Cancer Therapeutics, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Lung Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Lung Cancer Therapeutics Revenue Market Share by Type (2020-2025)
Table 28. Global Lung Cancer Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Lung Cancer Therapeutics Revenue Market Share by Type (2026-2031)
Table 30. Global Lung Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Lung Cancer Therapeutics Revenue Market Share by Application (2020-2025)
Table 32. Global Lung Cancer Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Lung Cancer Therapeutics Revenue Market Share by Application (2026-2031)
Table 34. North America Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Lung Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Lung Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Lung Cancer Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 49. AstraZeneca Company Details
Table 50. AstraZeneca Business Overview
Table 51. AstraZeneca Lung Cancer Therapeutics Product
Table 52. AstraZeneca Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 53. AstraZeneca Recent Development
Table 54. Eli Lilly and Company Company Details
Table 55. Eli Lilly and Company Business Overview
Table 56. Eli Lilly and Company Lung Cancer Therapeutics Product
Table 57. Eli Lilly and Company Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 58. Eli Lilly and Company Recent Development
Table 59. GlaxoSmithKline Company Details
Table 60. GlaxoSmithKline Business Overview
Table 61. GlaxoSmithKline Lung Cancer Therapeutics Product
Table 62. GlaxoSmithKline Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 63. GlaxoSmithKline Recent Development
Table 64. Roche Company Details
Table 65. Roche Business Overview
Table 66. Roche Lung Cancer Therapeutics Product
Table 67. Roche Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 68. Roche Recent Development
Table 69. Boehringer Ingelheim GmbH Company Details
Table 70. Boehringer Ingelheim GmbH Business Overview
Table 71. Boehringer Ingelheim GmbH Lung Cancer Therapeutics Product
Table 72. Boehringer Ingelheim GmbH Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 73. Boehringer Ingelheim GmbH Recent Development
Table 74. Pfizer Company Details
Table 75. Pfizer Business Overview
Table 76. Pfizer Lung Cancer Therapeutics Product
Table 77. Pfizer Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 78. Pfizer Recent Development
Table 79. Sanofi S.A. Company Details
Table 80. Sanofi S.A. Business Overview
Table 81. Sanofi S.A. Lung Cancer Therapeutics Product
Table 82. Sanofi S.A. Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 83. Sanofi S.A. Recent Development
Table 84. Bristol-Myers Squibb Company Details
Table 85. Bristol-Myers Squibb Business Overview
Table 86. Bristol-Myers Squibb Lung Cancer Therapeutics Product
Table 87. Bristol-Myers Squibb Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 88. Bristol-Myers Squibb Recent Development
Table 89. Novartis Company Details
Table 90. Novartis Business Overview
Table 91. Novartis Lung Cancer Therapeutics Product
Table 92. Novartis Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 93. Novartis Recent Development
Table 94. Agennix AG Company Details
Table 95. Agennix AG Business Overview
Table 96. Agennix AG Lung Cancer Therapeutics Product
Table 97. Agennix AG Revenue in Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 98. Agennix AG Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
Table 102. Authors List of This Report
List of Figures
Figure 1. Lung Cancer Therapeutics Picture
Figure 2. Global Lung Cancer Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Lung Cancer Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Targeted Therapy Features
Figure 5. Immunotherapy Features
Figure 6. Chemotherapy Features
Figure 7. Radiation Therapy Features
Figure 8. Others Features
Figure 9. Global Lung Cancer Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Lung Cancer Therapeutics Market Share by Application: 2024 VS 2031
Figure 11. Non-Small Cell Lung Cancer (NSCLC) Case Studies
Figure 12. Small Cell Lung Cancer (SCLC) Case Studies
Figure 13. Lung Cancer Therapeutics Report Years Considered
Figure 14. Global Lung Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Lung Cancer Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Lung Cancer Therapeutics Market Share by Region: 2024 VS 2031
Figure 17. Global Lung Cancer Therapeutics Market Share by Players in 2024
Figure 18. Global Top Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Cancer Therapeutics as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Lung Cancer Therapeutics Revenue in 2024
Figure 20. North America Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 22. United States Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 26. Germany Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Lung Cancer Therapeutics Market Share by Region (2020-2031)
Figure 34. China Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 42. Mexico Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Lung Cancer Therapeutics Market Share by Country (2020-2031)
Figure 46. Turkey Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. AstraZeneca Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 50. Eli Lilly and Company Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 51. GlaxoSmithKline Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 52. Roche Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 53. Boehringer Ingelheim GmbH Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 54. Pfizer Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 55. Sanofi S.A. Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 57. Novartis Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 58. Agennix AG Revenue Growth Rate in Lung Cancer Therapeutics Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232